BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/12/2024 12:30:50 PM | Browse: 227 | Download: 803
Publication Name World Journal of Orthopedics
Manuscript ID 94859
Country China
ISSN 2218-5836 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pharmacology & Pharmacy
Manuscript Type Editorial
Article Title Evolution of treatment options for juvenile idiopathic arthritis
Manuscript Source Invited Manuscript
All Author List Tao Ren, Jia-Hui Guan, Yu Li, Nan-Nan Li and Zheng Li
ORCID
Author(s) ORCID Number
Nan-Nan Li http://orcid.org/0009-0007-8740-5201
Zheng Li http://orcid.org/0000-0002-2882-6600
Funding Agency and Grant Number
Corresponding Author Zheng Li, PhD, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com
Key Words Juvenile idiopathic arthritis; Treatment; Non-steroidal anti-inflammatory drug; Disease-modifying antirheumatic drug; Evolution
Core Tip In past decades, the pharmacological treatments for juvenile idiopathic arthritis (JIA) have undergone a dramatic evolution from non-steroidal anti-inflammatory drugs to disease-modifying antirheumatic drugs (DMARDs), especially the emergence of biologic DMARDs enable patients with refractory JIA to achieve disease remission. This editorial focuses on the progress in treatment options for JIA. We hope that this editorial could provide valuable information for use of anti-JIA drugs.
Publish Date 2024-09-12 12:30
Citation

Ren T, Guan JH, Li Y, Li NN, Li Z. Evolution of treatment options for juvenile idiopathic arthritis. World J Orthop 2024; 15(9): 831-835

URL https://www.wjgnet.com/2218-5836/full/v15/i9/831.htm
DOI https://dx.doi.org/10.5312/wjo.v15.i9.831
Full Article (PDF) WJO-15-831-with-cover.pdf